PharVision Advisers’s Ventas VTR Stock Holding History

PharVision Advisers’s Portfolio VTR Stock Details VTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,111	Closed	-$283K	–	444
2025 Q1	$283K	Sell	4,111 -607	-13%	-$38.8K	0.39%	104
2024 Q4	$278K	Buy	+4,718	New	+$296K	0.23%	183

Other funds holding VTR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAMU

APG Asset Management US New York $13B AUM 5.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIM

Centersquare Investment Management Conshohocken, Pennsylvania $9.67B AUM 5.55% 1-Year Est. Return

PharVision Advisers's VTR Position: Q2 2025 in Review

PharVision Advisers sold out of Ventas (VTR) in Q2 2025, closing a stake of 4,111 shares — an estimated $283K sold.

PharVision Advisers first reported a position in VTR in Q4 2024 and held it in 2 quarters. The position peaked at $283K in Q1 2025. 797 funds tracked by Wall St. Rank hold VTR as of Q2 2025.

PharVision Advisers reported no remaining Ventas position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 4,111 Ventas shares in Q2 2025, an estimated $283K.
PharVision Advisers first reported a position in Ventas in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Ventas position peaked at $283K in Q1 2025.
797 funds tracked by Wall St. Rank held Ventas as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.